Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Share-based Compensation: 2020-2025

Historic Share-based Compensation for Silence Therapeutics (SLN) over the last 5 years, with Sep 2025 value amounting to $2.5 million.

  • Silence Therapeutics' Share-based Compensation fell 37.67% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 million, marking a year-over-year decrease of 14.46%. This contributed to the annual value of $16.3 million for FY2024, which is 0.20% up from last year.
  • Latest data reveals that Silence Therapeutics reported Share-based Compensation of $2.5 million as of Q3 2025, which was up 21.58% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Silence Therapeutics' Share-based Compensation registered a high of $5.7 million during Q1 2023, and its lowest value of $1.9 million during Q4 2023.
  • Its 3-year average for Share-based Compensation is $3.7 million, with a median of $4.0 million in 2024.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 113.12% in 2024, then tumbled by 49.65% in 2025.
  • Quarterly analysis of 5 years shows Silence Therapeutics' Share-based Compensation stood at $2.5 million in 2021, then dropped by 18.52% to $2.0 million in 2022, then fell by 7.68% to $1.9 million in 2023, then spiked by 113.12% to $4.0 million in 2024, then plummeted by 37.67% to $2.5 million in 2025.
  • Its last three reported values are $2.5 million in Q3 2025, $2.1 million for Q2 2025, and $3.5 million during Q1 2025.